These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2279545)

  • 1. Alpha-2b-interferon as single therapy for patients with chronic myeloid leukemia relapsing after T-cell depleted allogeneic bone marrow transplantation.
    Arcese W; Mauro FR; Screnci M; Alimena G; Iori AP; De Cuia MR; Lo Coco F; Montefusco E; Fazi P; Mandelli F
    Eur J Haematol Suppl; 1990; 52():36-9. PubMed ID: 2279545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon therapy for Ph1 positive CML patients relapsing after T cell-depleted allogeneic bone marrow transplantation.
    Arcese W; Mauro FR; Alimena G; Lo Coco F; De Cuia MR; Screnci M; Iori AP; Montefusco E; Mandelli F
    Bone Marrow Transplant; 1990 May; 5(5):309-15. PubMed ID: 2350627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation.
    Higano CS; Chielens D; Raskind W; Bryant E; Flowers ME; Radich J; Clift R; Appelbaum F
    Blood; 1997 Oct; 90(7):2549-54. PubMed ID: 9326220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Elmaagacli AH; Beelen DW; Schaefer UW
    Bone Marrow Transplant; 1997 Dec; 20(12):1045-55. PubMed ID: 9466277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of alpha interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation.
    Higano CS; Raskind WH; Singer JW
    Blood; 1992 Sep; 80(6):1437-42. PubMed ID: 1520870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected].
    Klingemann HG; Grigg AP; Wilkie-Boyd K; Barnett MJ; Eaves AC; Reece DE; Shepherd JD; Phillips GL
    Blood; 1991 Dec; 78(12):3306-11. PubMed ID: 1742491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant alpha-interferon as treatment for chronic myelogenous leukemia in relapse after allogeneic bone marrow transplantation: a report from the Société Française de Greffe de Moelle.
    Pigneux A; Devergie A; Pochitaloff M; Rio B; Archimbaud E; Cahn JY; Leblond V; Michallet M; Jouet JP; Guilhot F
    Bone Marrow Transplant; 1995 Jun; 15(6):819-24. PubMed ID: 7581075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case report of spontaneous remission of cytogenetic relapse of chronic myelogenous leukemia suggestive of progression to blast crisis after allogeneic bone marrow transplantation.
    Agaliotis DP; Papenhausen PR; Moscinski LC; Elfenbein GJ
    Ann Hematol; 1995 Jan; 70(1):37-41. PubMed ID: 7827205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of interferon alfa-2a to treat hematologic relapse of chronic myelogenous leukemia after bone marrow transplantation.
    Higano CS; Raskind WH; Singer JW
    Acta Haematol; 1993; 89 Suppl 1():8-14. PubMed ID: 8475671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation.
    Steegmann JL; Casado LF; Tomás JF; Sanz-Rodríguez C; Granados E; de la Cámara R; Alegre A; Vázquez L; Ferro MT; Figuera A; Arranz R; Fernández-Rañada JM
    Bone Marrow Transplant; 1999 Mar; 23(5):483-8. PubMed ID: 10100563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The maintenance of busulphan-induced remissions in chronic granulocytic leukaemia with recombinant interferon alpha-2b.
    Bergsagel DE; Messner H
    Br J Cancer; 1990 Jun; 61(6):895-8. PubMed ID: 2372493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular remission achieved by interferon therapy in a patient with cytogenetically relapsed chronic myelogenous leukemia after syngeneic bone marrow transplantation.
    Yano K; Iijima K; Sao H; Kobayashi M
    Int J Hematol; 1996 Oct; 64(3-4):267-70. PubMed ID: 8923790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
    Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
    Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia.
    Mackinnon S; Barnett L; Heller G
    Bone Marrow Transplant; 1996 Apr; 17(4):643-7. PubMed ID: 8722369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving modalities of treatment with interferon alfa-2b for Ph1-positive chronic myelogenous leukaemia.
    Morra E; Alimena G; Lazzarino M; Liberati AM; Montefusco E; Bernasconi P; Mancini M; Donti E; Merante S; Dianzani F
    Eur J Cancer; 1991; 27 Suppl 4():S14-7. PubMed ID: 1799466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy-induced Ph1 suppression in chronic myeloid leukemia: molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion.
    Lo Coco F; Mandelli F; Diverio D; Alimena G; De Fabritiis P; Meloni G; Cedrone M; Frontani M; Guerrasio A; Saglio G
    Bone Marrow Transplant; 1990 Oct; 6(4):253-8. PubMed ID: 2085700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Good predictive value of combined cytogenetic and molecular follow up in chronic myelogenous leukemia after non T-cell depleted allogeneic bone marrow transplantation: a report on 38 consecutive cases.
    Preudhomme C; Wattel E; Lai JL; Henic N; Meyer L; Noel MP; Cosson A; Jouet JP; Fenaux P
    Leuk Lymphoma; 1995 Jul; 18(3-4):265-71. PubMed ID: 8535192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon alpha-2b as therapy for patients with Ph'-positive chronic myelogenous leukemia.
    Alimena G; Morra E; Lazzarino M; Liberati AM; Montefusco E; Inverardi D; Bernasconi P; Mancini M; Donti E; Grignani F
    Eur J Haematol Suppl; 1990; 52():25-8. PubMed ID: 2279541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
    Silver RT; Peterson BL; Szatrowski TP; Powell BL; Stock W; Carroll AJ; Bloomfield CD; Schiffer CA; Larson RA
    Leuk Lymphoma; 2003 Jan; 44(1):39-48. PubMed ID: 12691141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.